Company Profile
Minerva Neuroscience Stock Price, News & Catalysts
- Ticker:
- NERV
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.66 USD (+5.78%)
Close
Last updated: September 18, 2026
221M USD
Market cap
Why the stock is moving
As of Sep 18, 2026, NERV closed up 5.78% at $3.66. No new same-company headline was identified in the current news window.
Company overview
CNS Drug Development
Minerva Neurosciences develops therapies for central nervous system disorders. Its lead program focuses specifically on negative symptoms of schizophrenia, an area with limited approved treatment options.
Roluperidone
Roluperidone is an investigational oral therapy intended to improve primary negative symptoms such as social withdrawal, reduced emotional expression and lack of motivation. Earlier studies demonstrated clinically meaningful effects without relying on dopamine D2 blockade.
Confirmatory Registration Path
Minerva has general FDA alignment on a confirmatory Phase 3 study using a design similar to its prior trials. The approximately 380-patient first phase will compare 64 mg roluperidone with placebo over 12 weeks and is intended to support NDA resubmission.
Future catalysts
- Initiation of the confirmatory Phase 3 roluperidone trial planned for the second quarter of 2026.
- Topline Phase 3 data anticipated in the second half of 2027.
- Potential NDA resubmission following successful completion of the confirmatory study.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Minerva Neuroscience (NERV)?
Minerva Neuroscience (NERV) most recently closed at 3.66 USD, a +5.78% move versus the previous session.
What is the market cap of Minerva Neuroscience (NERV)?
Minerva Neuroscience currently has a market capitalization of 221M USD on BioPharmSignal.
What does Minerva Neuroscience do?
CNS Drug Development Minerva Neurosciences develops therapies for central nervous system disorders. Its lead program focuses specifically on negative symptoms of schizophrenia, an area with limited approved treatment options. Roluperidone Roluperidone is an investigational oral therapy intended to improve primary negative symptoms such as social withdrawal,...
On which exchange is NERV stock listed?
Minerva Neuroscience (NERV) is associated with NASDAQ, United States, Biopharma.
What is Drug?
CNS Drug Development Minerva Neurosciences develops therapies for central nervous system disorders.
Which conditions is Minerva Neuroscience targeting with Drug?
Minerva Neuroscience is associated with neuroscience based on its company overview and current catalyst commentary.
How does Minerva Neuroscience describe recent progress with Drug?
Initiation of the confirmatory Phase 3 roluperidone trial planned for the second quarter of 2026. Topline Phase 3 data anticipated in the second half of 2027. Potential NDA resubmission following successful completion of the confirmatory study.
What is Development?
CNS Drug Development Minerva Neurosciences develops therapies for central nervous system disorders.